SCHEMBL285837

SCHEMBL285837

ClCc1conc1-c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 7/20 0.45
KDM4E B2RXH2 5/20 0.42
LMNA P02545 3/20 0.42
CCR1 P32246 2/20 0.42
CCR5 P51681 2/20 0.42
CCR8 P51685 2/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
METAP1 P53582 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
DOHH Q9BU89 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
NPC1 O15118 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 4/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 3/20 0.37
HTT P42858 3/20 0.37
TDP1 Q9NUW8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285687 0.83 GABRA5 (0.49) GABRA5KDM4ELMNACCR1CCR5
SCHEMBL3213310 0.75 PTGS2 (0.41) GABRA5KDM4ELMNACYP1A2BLM
SCHEMBL4782258 0.75 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1778022 0.74 GABRA5 (0.53) GABRA5NPC1SMN1; SMN2RAB9ATP53
SCHEMBL30888443 0.71 KDM4E (0.43) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5250144 0.71 HSP90AA1 (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL4781710 0.71 KDM4E (0.43) KDM4ELMNACCR1CCR5CCR8
SCHEMBL4600282 0.69 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL285546 0.69 KDM4E (0.45) GABRA5KDM4ELMNACCR1CCR5
Hydrochloric Acid SCHEMBL14856755 0.68 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-B1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN LA ROCHE (CH) 2016-09-28 EP disclosed
US-8178522-B2 Thiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127974-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286116-A1 THIAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286116-A1 THIAZOLES GABRA5, GABRA1, GABRA4 GABRA5 1/4885KDM4E 2938/4885LMNA 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.